Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
(S)-H1, an IRF4 binder that targets SPI1-IRF4 interaction on IRF4’s interferon association domain, shows pre-clinial anti-myeloma activity when converted into proteolysis-targeting chimera w/ E3 sequence binding Cereblon.”
Title: Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma
Authors: Michael P. Agius, Chen Song, Qi Liu, Tomoki Iemura, Laura Hevenor, N. Connor Payne, Romanos Sklavenitis Pistofidis, Lorena Pantano, Hongfang Zhao, Hyuk-Soo Seo, Daniel Heilpern-Mallory, Caleb Heaslip, Zhen-Yu J. Sun, Puspalata Bashyal, Michelle P. Aranha, Elizabeth Lightbody, Ralph Mazitschek, Sirano Dhe-Paganon, Constantine S. Mitsiades, Irene M. Ghobrial, Jun Qi
You can read the Full Article on Nature Chemical Biology.
You can find other articles featuring Robert Orlowski on OncoDaily.
